ImageneBio (IMA) Preferred Stock Liabilities (2020 - 2023)
ImageneBio's (IMA) quarterly Preferred Stock Liabilities came in at $31.8 million in Q3 2023, down 84.54% quarter-over-quarter from $206.0 million in Q4 2020.
ImageneBio (IMA) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends
ImageneBio has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $31.8 million for Q3 2023.
- Preferred Stock Liabilities for Q3 2023 came in at $31.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $31.8 million (changed N/A YoY), and the FY2020 annual result was $206.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $31.8 million for Q3 2023 at ImageneBio, down from $206.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $206.0 million in Q4 2020 to a low of $31.8 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImageneBio | 3.18 Mn | 3.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 31.85 Mn |
| Dec 31, 2020 | 205.98 Mn |
| Sep 30, 2020 | 78.87 Mn |
| Jun 30, 2020 | 78.87 Mn |
| Mar 31, 2020 | 78.87 Mn |